Related Experiment Video
Updated: Oct 9, 2025
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Secretin Stimulation Test and Early Diagnosis of Gastrinoma in MEN1 Syndrome: Survey on the MEN1 Florentine Database
Francesca Giusti1, Federica Cioppi2, Caterina Fossi1
1Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Context:
Multiple endocrine neoplasia type 1 (MEN1) is a rare inherited endocrine cancer syndrome. Multiple gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) affect 30% to 80% of MEN1 patients, with the most common functioning GEP-NET being gastrinoma. Biochemical identification of hypergastrinemia may help to recognize the presence of gastrinomas before they are detectable by instrumental screening, enabling early diagnosis and start of therapy, preferably before tumor progression and metastases occurrence.
Objective:
Evaluate the effectiveness of secretin stimulation test to precociously diagnose the presence of gastrin-secreting tumors.
Design:
Results of secretin stimulation tests, performed between 1991 and February 2020, were retrospectively analyzed, as aggregate, in a cohort of MEN1 patients with GEP-NETs.
Setting:
Data were extracted from the MEN1 Florentine database.
Patients:
The study included 72 MEN1 patients with GEP-NETs who underwent a secretin stimulation test for the evaluation of gastrin secretion.
Outcomes:
A positive secretin stimulation test was assumed with a difference between basal fasting serum gastrin (FSG) and the maximum stimulated value of gastrin over 120 pg/mL.
Results:
The secretin stimulation test showed a secretin-induced hypergastrinemia in 27.8% (20/72) of patients with GEP-NETs, and a positive test in 18 cases. The test allowed the identification of a positively stimulated hypergastrinemia in 75.0% (3/4) of patients who presented a basal FSG within the normal range.
Conclusions:
Diagnosis of gastrinoma is complex, difficult, and controversial. Results of this study confirm that a positive secretin stimulation test allows early diagnosis of gastrinomas, even in the presence of borderline or normal levels of nonstimulated FSG.
Insights
The secretin stimulation test effectively identifies gastrinomas in Multiple Endocrine Neoplasia type 1 (MEN1) patients. This test aids early gastrinoma diagnosis, even with normal fasting serum gastrin levels.
Area of Science:
- Endocrinology
- Oncology
- Gastroenterology
Background:
- Multiple Endocrine Neoplasia type 1 (MEN1) is a rare inherited endocrine cancer syndrome.
- Gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) affect 30-80% of MEN1 patients, with gastrinoma being the most common functioning GEP-NET.
- Early diagnosis of gastrinomas is crucial to prevent tumor progression and metastasis.
Purpose of the Study:
- To evaluate the effectiveness of the secretin stimulation test for the early diagnosis of gastrin-secreting tumors in MEN1 patients.
Main Methods:
- Retrospective analysis of secretin stimulation tests performed between 1991 and February 2020 in a cohort of MEN1 patients with GEP-NETs.
- Data extracted from the MEN1 Florentine database.
- A positive test was defined by a gastrin increase >120 pg/mL after secretin stimulation.
Main Results:
- The secretin stimulation test induced hypergastrinemia in 27.8% (20/72) of patients with GEP-NETs, with 18 cases showing a positive test.
- The test identified positively stimulated hypergastrinemia in 75.0% (3/4) of patients with normal basal fasting serum gastrin (FSG) levels.
Conclusions:
- Diagnosis of gastrinoma can be complex and challenging.
- A positive secretin stimulation test facilitates early gastrinoma diagnosis in MEN1 patients.
- The test is valuable even when non-stimulated FSG levels are borderline or normal.
Related Concept Videos
01:50What is Monogastric Digestion?
01:30Serum Laboratory Studies, Stool Test, Breath Test